Swedish Orphan Biovitrum AB (Sobi) today published its Annual Report for 2012, themed "Building value for patients, partners and shareholders", on the company's website, www.sobi.com.
The report encompasses the company's approach to keeping the patient journey - from diagnosis and treatment, to on-going disease management and long-term outcomes - at the centre of how it prioritises its capabilities and investments. By creating and maintaining a dialogue with key stakeholders (patients organizations, physicians, governments and payers), Sobi seeks to ensure that treatments are delivered in a sustainable way. Sobi refers to this approach as Patient and Customer Centric commercialisation. --- About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com For more information - not for publication Media relations Investor relations Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations T: +46 70 410 71 80 T: +1 347 224 0819 [email protected] [email protected]
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.